Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc.LCTX · Entity 6045 | Director | July 01, 2026 | July 02, 2026 |
| STAAR SURGICAL COSTAA · Entity 4851 | Chief Financial Officer & EVP | August 14, 2026 | August 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Lineage Cell Therapeutics, Inc.
Report date July 01, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.30 · Expires 2036-07-01 | Direct | 125,000 |
Reported balance
After 2026-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 125,000 · Balance 125,000 F1: Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Will vest and become exercisable on the earlier of July 1, 2027 and the date of the issuer's next annual meeting of shareholders, subject in any case to the reporting person's continuous service with the issuer.
STAAR SURGICAL CO
Report date August 14, 2026 · Filed August 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,452 |
Reported balance
After 2026-08-14 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2026-08-14 · Exercise / conversion · Acquired 5,233 · Balance 41,452 |
| Common StockSEC Table I · non-derivative | Direct | 38,910 |
Reported balance
After 2026-08-14 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2026-08-14 · Tax withholding · Disposed 2,662 · Balance 38,910 F1: On May 15, 2026, the third tranche of 5,233 performance stock units ("PSUs") awarded to the Reporting Person under the 2025 PSU Program in connection with her new hire grant vested, of which 2,662 shares were withheld to satisfy taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 4,975 |
Reported balance
After 2026-08-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-14 · Grant · Acquired 4,975 · Balance 4,975 F2: Each restricted stock unit ("RSU") represents the right to receive one share of STAAR Surgical Company ("Company") common stock upon vesting. F3: The Reporting Person was granted Company RSUs on August 14, 2026 (the "Grant Date"). These RSUs vest as to one-third on the first anniversary of the Grant Date, and the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter. F4: The Reporting Person was granted Issuer restricted stock units (RSUs) on August 14, 2026 (the "Grant Date"). These RSUs vest as to one-third on the first anniversary of the Grant Date, and the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.18 · Expires 2036-08-13 | Direct | 8,952 |
Reported balance
After 2026-08-14 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-08-14 · Grant · Acquired 8,952 · Balance 8,952 F5: The Reporting Person was granted an option to purchase 8,952 shares of Company common stock. The shares underlying the option vest over three years from the Grant Date, with one-third vesting on the first anniversary of the Grant Date and the remaining two-thirds vesting in 24 substantially equal monthly installment thereafter. |
| Performance Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.18 · Expires 2036-08-13 | Direct | 29,159 |
Reported balance
After 2026-08-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-08-14 · Grant · Acquired 29,159 · Balance 29,159 F6: The Reporting Person was granted a performance option to purchase 29,159 shares of Company common stock. The shares underlying the option vest over a performance period ending on the earlier of a change in control and the 10-year anniversary of the Grant Date, subject to achievement of stock-price hurdles of $50.00, $75.00 and $100.00 per share, and time vest as to one-third on the anniversary of the Grant Date with the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter. |
| Performance Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2027-12-31 | Direct | 41,452 |
Reported balance
After 2026-08-14 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-14 · Exercise / conversion · Acquired 5,233 · Balance 41,452 F7: Represents the settlement of the third tranche of PSUs awarded to the Reporting Person in connection with her new hire grant under the 2025 PSU Program. The number of shares earned was determined upon certification by the Compensation Committee based on achievement of applicable performance goals. The original grant was exempt pursuant to Rule 16b-3(d) and was not previously reported. |
Filing footnotes · ownership attribution and instrument terms
F1: On May 15, 2026, the third tranche of 5,233 performance stock units ("PSUs") awarded to the Reporting Person under the 2025 PSU Program in connection with her new hire grant vested, of which 2,662 shares were withheld to satisfy taxes.
F2: Each restricted stock unit ("RSU") represents the right to receive one share of STAAR Surgical Company ("Company") common stock upon vesting.
F3: The Reporting Person was granted Company RSUs on August 14, 2026 (the "Grant Date"). These RSUs vest as to one-third on the first anniversary of the Grant Date, and the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter.
F4: The Reporting Person was granted Issuer restricted stock units (RSUs) on August 14, 2026 (the "Grant Date"). These RSUs vest as to one-third on the first anniversary of the Grant Date, and the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter.
F5: The Reporting Person was granted an option to purchase 8,952 shares of Company common stock. The shares underlying the option vest over three years from the Grant Date, with one-third vesting on the first anniversary of the Grant Date and the remaining two-thirds vesting in 24 substantially equal monthly installment thereafter.
F6: The Reporting Person was granted a performance option to purchase 29,159 shares of Company common stock. The shares underlying the option vest over a performance period ending on the earlier of a change in control and the 10-year anniversary of the Grant Date, subject to achievement of stock-price hurdles of $50.00, $75.00 and $100.00 per share, and time vest as to one-third on the anniversary of the Grant Date with the remaining two-thirds vesting in 24 substantially equal monthly installments thereafter.
F7: Represents the settlement of the third tranche of PSUs awarded to the Reporting Person in connection with her new hire grant under the 2025 PSU Program. The number of shares earned was determined upon certification by the Compensation Committee based on achievement of applicable performance goals. The original grant was exempt pursuant to Rule 16b-3(d) and was not previously reported.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 21, 2020 Filed Jan 23, 2020 21:06 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Stock | 20,000 | $11.00 | $220,000.00 |
DisclosureSEC source: 0001209191-20-004627 · doc4.xml · nonDerivative · entry 1 ANDREWS DEBORAH J · CIK 0001325697 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,101 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 14, 2019 Filed Nov 15, 2019 21:15 UTC | STAAR SURGICAL CO STAA · Entity 4851 | SaleCommon Stock | 4,167 | $34.68 | $144,511.56 |
DisclosureSEC source: 0001209191-19-056725 · doc4.xml · nonDerivative · entry 1 ANDREWS DEBORAH J · CIK 0001325697 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,101 Read SEC document |
| July 01, 2019 Filed Jul 4, 2019 01:25 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001209191-19-041314 · doc4.xml · derivative · entry 1 ANDREWS DEBORAH J · CIK 0001325697 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2029-06-30 F1 · derivative.exercise_date: Will become exercisable on June 30, 2020, based upon continued service on the board of directors. Read SEC document |
| April 04, 2019 Filed Apr 5, 2019 20:04 UTC | STAAR SURGICAL CO STAA · Entity 4851 | SaleCommon Stock | 1,000 | $34.35 | $34,350.00 |
DisclosureSEC source: 0001209191-19-023797 · doc4.xml · nonDerivative · entry 1 ANDREWS DEBORAH J · CIK 0001325697 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,268 Read SEC document |
| March 22, 2019 Filed Mar 22, 2019 20:11 UTC | STAAR SURGICAL CO STAA · Entity 4851 | SaleCommon Stock | 833 | $38.88 | $32,387.04 |
DisclosureSEC source: 0001209191-19-020997 · doc4.xml · nonDerivative · entry 1 ANDREWS DEBORAH J · CIK 0001325697 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,268 Read SEC document |
| March 14, 2019 Filed Mar 15, 2019 20:02 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantCommon Stock Options · Derivative | 16,883 | $0.00 Strike: $35.98 | $0.00 |
DisclosureSEC source: 0001209191-19-019673 · doc4.xml · derivative · entry 1 ANDREWS DEBORAH J · CIK 0001325697 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,883 Underlying: Common Stock · 16,883 shares Expires 2029-03-13 F1 · security: The options granted become exercisable as follows: 1/3 on 3/14/2020 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 3/14/2022. Read SEC document |
| September 11, 2018 Filed Sep 13, 2018 20:17 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | PurchaseCommon Shares, no par value | 1,604 | $2.35 | $3,769.40 |
DisclosureSEC source: 0001209191-18-050839 · doc4.xml · nonDerivative · entry 1 ANDREWS DEBORAH J · CIK 0001325697 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| July 01, 2018 Filed Jul 3, 2018 22:04 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GrantOption to Purchase Common Shares · Derivative | 40,000 | $0.00 Strike: $2.06 | $0.00 |
DisclosureSEC source: 0001209191-18-041291 · doc4.xml · derivative · entry 2 ANDREWS DEBORAH J · CIK 0001325697 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2023-06-30 F1 · derivative.exercise_date: Will become exercisable on June 30, 2019, based upon continued service on the board of directors. Read SEC document |
| June 14, 2018 Filed Jun 14, 2018 21:27 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantCommon Stock Options · Derivative | 6,742 | $0.00 Strike: $29.80 | $0.00 |
DisclosureSEC source: 0001209191-18-037804 · doc4.xml · derivative · entry 1 ANDREWS DEBORAH J · CIK 0001325697 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,742 Underlying: Common Stock · 6,742 shares Expires 2028-06-13 Read SEC document |
| June 14, 2018 Filed Jun 15, 2018 10:11 UTC Amendment | STAAR SURGICAL CO STAA · Entity 4851 | GrantCommon Stock · Derivative | 6,742 | $0.00 Strike: $29.80 | $0.00 |
DisclosureSEC source: 0001209191-18-037932 · doc4a.xml · derivative · entry 1 ANDREWS DEBORAH J · CIK 0001325697 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,742 Underlying: Common Stock · 6,742 shares Expires 2028-06-13 F1 · security: The options granted become exercisable as follows: 1/3 on 6/14/2019 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 6/14/2021. Read SEC document |
| May 07, 2018 Filed May 7, 2018 20:06 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Stock · Derivative | 25,000 | $0.00 Strike: $5.68 | $0.00 |
DisclosureSEC source: 0001209191-18-028286 · doc4.xml · derivative · entry 5 ANDREWS DEBORAH J · CIK 0001325697 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2020-12-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: These stock options became exercisable in three equal annual installments on December 15, 2011, December 15, 2012, and December 15, 2013. Read SEC document |
| May 07, 2018 Filed May 7, 2018 20:06 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Stock | 25,000 | $5.68 | $142,000.00 |
DisclosureSEC source: 0001209191-18-028286 · doc4.xml · nonDerivative · entry 3 ANDREWS DEBORAH J · CIK 0001325697 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2018 Filed May 7, 2018 20:06 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Stock · Derivative | 13,331 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001209191-18-028286 · doc4.xml · derivative · entry 4 ANDREWS DEBORAH J · CIK 0001325697 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,331 shares Expires 2018-05-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: These stock options became exercisable in three equal annual installments on May 15, 2009, May 15, 2010, and May 15, 2011. Read SEC document |
| May 03, 2018 Filed May 7, 2018 20:06 UTC | STAAR SURGICAL CO STAA · Entity 4851 | SaleCommon Stock | 13,331 | $17.60 | $234,625.60 |
DisclosureSEC source: 0001209191-18-028286 · doc4.xml · nonDerivative · entry 2 ANDREWS DEBORAH J · CIK 0001325697 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,667 Read SEC document |
| May 03, 2018 Filed May 7, 2018 20:06 UTC | STAAR SURGICAL CO STAA · Entity 4851 | Exercise / conversionCommon Stock | 13,331 | $2.91 | $38,793.21 |
DisclosureSEC source: 0001209191-18-028286 · doc4.xml · nonDerivative · entry 1 ANDREWS DEBORAH J · CIK 0001325697 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 22, 2018 Filed Mar 22, 2018 16:46 UTC | STAAR SURGICAL CO STAA · Entity 4851 | SaleCommon Stock | 333 | $16.05 | $5,344.65 |
DisclosureSEC source: 0001209191-18-021210 · doc4.xml · nonDerivative · entry 1 ANDREWS DEBORAH J · CIK 0001325697 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,667 Read SEC document |
| March 15, 2018 Filed Mar 19, 2018 21:21 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantCommon Stock Options · Derivative | 12,500 | $0.00 Strike: $16.15 | $0.00 |
DisclosureSEC source: 0001209191-18-020650 · doc4.xml · derivative · entry 1 ANDREWS DEBORAH J · CIK 0001325697 · Vice President · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-03-14 F1 · security: The options granted become exercisable as follows: 1/3 on 03/15/2019, and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 03/15/2021. Read SEC document |
| November 13, 2017 Filed Sep 28, 2017 19:13 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-054237 · doc4.xml · nonDerivative · entry 1 ANDREWS DEBORAH J · CIK 0001325697 · Vice President · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 F1 · security: Award of 12,500 Restricted Stock Units of Common Stock (RSU), subject to forfeiture rights, which lapse as to 1/3 of the RSUs on 11/13/2018, 1/3 of the RSUs on 11/13/2019, and the remaining 1/3 of the RSUs on 11/13/2020. Read SEC document |
| September 26, 2017 Filed Sep 28, 2017 19:13 UTC | STAAR SURGICAL CO STAA · Entity 4851 | GrantCommon Stock Options · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-054237 · doc4.xml · derivative · entry 2 ANDREWS DEBORAH J · CIK 0001325697 · Vice President · CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-09-25 F2 · security: The options granted become exercisable as follows: 1/3 on 11/13/2018, and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 11/13/2020. F3 · derivative.exercise_price: The exercise price of each option granted on 9/26/17 will be the fair market value of the Common Stock of the Corporation as of the close of business on 11/13/17. Read SEC document |
| August 21, 2017 Filed Aug 23, 2017 22:31 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | PurchaseCommon Shares, no par value | 2,396 | $2.50 | $5,990.00 |
DisclosureSEC source: 0001209191-17-050000 · doc4.xml · nonDerivative · entry 1 ANDREWS DEBORAH J · CIK 0001325697 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,396 Read SEC document |
| July 01, 2017 Filed Jul 5, 2017 23:36 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | GrantOption to Purchase Common Shares · Derivative | 20,000 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001209191-17-043769 · doc4.xml · derivative · entry 2 ANDREWS DEBORAH J · CIK 0001325697 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2022-06-30 F1 · derivative.exercise_date: Will become exercisable in four equal quarterly installments after the date of grant on July 1, 2017 based upon continued service on the board of directors. Read SEC document |
| June 16, 2017 Filed Jun 22, 2017 00:19 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | PurchaseCommon Shares, no par value | 2,000 | $2.95 | $5,900.00 |
DisclosureSEC source: 0001209191-17-041267 · doc4.xml · nonDerivative · entry 1 ANDREWS DEBORAH J · CIK 0001325697 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Read SEC document |
| May 16, 2017 Filed May 18, 2017 00:52 UTC | Lineage Cell Therapeutics, Inc. BTX · Entity 6045 | PurchaseCommon Shares, no par value | 2,000 | $3.21 | $6,410.40 |
DisclosureSEC source: 0001209191-17-033460 · doc4.xml · nonDerivative · entry 1 ANDREWS DEBORAH J · CIK 0001325697 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.